Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Castle Biosciences Inc (NQ: CSTL )

24.92 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11
Open 24.92
Bid (Size) 18.50 (1)
Ask (Size) 26.00 (4)
Prev. Close 24.92
Today's Range 24.92 - 24.92
52wk Range 9.260 - 26.70
Shares Outstanding 25,167,365
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
From Castle Biosciences Inc.
Via Business Wire

Performance

YTD
+13.48%
+13.48%
1 Month
+27.08%
+27.08%
3 Month
-0.68%
-0.68%
6 Month
+28.59%
+28.59%
1 Year
-0.32%
-0.32%

More News

Read More
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
From Castle Biosciences Inc.
Via Business Wire
Recap: Castle Biosciences Q4 Earnings
Via Benzinga
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
From Castle Biosciences Inc.
Via Business Wire
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
From Castle Biosciences Inc.
Via Business Wire
CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Castle Biosciences Reports First Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Announces Updates to its Board of Directors
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
From Castle Biosciences Inc.
Via Business Wire
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
From Castle Biosciences Inc.
Via Business Wire
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
From Castle Biosciences Inc.
Via Business Wire
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
From Castle Biosciences Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
From Castle Biosciences Inc.
Via Business Wire
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.